Document is current

Article History

Received: 25 September 2024

Accepted: 16 January 2025

First Online: 3 February 2025

Declarations

:

: Moritz T. Huttelmaier (MTH) reports travel grants from BIOTRONIK SE & Co. KG, Erlangen, Germany, and speaker fees from C.T.I GmbH, Duesseldorf, Germany. Alexander Gabel (AG) declares no conflicts of interests. Stefan Franz-Josef Störk (SFS) has received consultancy and lecture fees as well as support/travel grants for meetings from Alnylam, AstraZeneca, Bayer, Boehringer-Ingelheim, Cytogenetics, Ionis, MSD, Novartis, and Servier. He states participation on a data safety monitoring board or advisory board from AstraZeneca, Bayer, Boehringer-Ingelheim, Pharmacosmos, NovoNordisk, and Pfizer. Stefan Frantz (SF) is supported by the DFG. He has received consultancy and lecture fees as well as support/ travel grants from Abbot, Abiomed, Amarin, Amgen, AstraZeneca, Bayer, Berlin-Chemie, Biotronik, Boehringer, Bristol-Myers Squibb, Boehringer, Daiichi Sankyo, Edwards, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Siemens, Vifor, and Zoll. Caroline Morbach (CM) received advisory and speakers’ honoraria as well as travel grants from TOMTEC, Edwards, Alnylam, Pfizer, Boehringer Ingelheim, Eli Lilly, AstraZeneca, NovoNordisk, Alexion, Janssen, Bayer, Intellia, and EBR Systems; she serves as principal investigator in trials sponsored by Alnylam, Bayer, NovoNordisk, Intellia, and AstraZeneca. Thomas H. Fischer (THF) received travel grants from BIOTRONIK SE & Co. KG, Erlangen, Germany, and speaker fees from C.T.I GmbH, Duesseldorf, Germany.